1 Hoeper, M. M. et al. A global view of pulmonary hypertension. Lancet Respir Med 4, 306-322, doi:10.1016/S2213-2600(15)00543-3 (2016).
2 Sakao, S., Tatsumi, K. & Voelkel, N. F. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res 10, 95, doi:10.1186/1465-9921-10-95 (2009).
3 Humbert, M. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53, doi:10.1183/13993003.01887-2018 (2019).
4 Dannewitz Prosseda, S., Ali, M. K. & Spiekerkoetter, E. Novel Advances in Modifying BMPR2 Signaling in PAH. Genes (Basel) 12, doi:10.3390/genes12010008 (2020).
5 Yuan, J. X. & Rubin, L. J. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111, 534-538, doi:10.1161/01.CIR.0000156326.48823.55 (2005).
6 Southgate, L., Machado, R. D., Graf, S. & Morrell, N. W. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol 17, 85-95, doi:10.1038/s41569-019-0242-x (2020).
7 Long, L. et al. Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res 112, 1159-1170, doi:10.1161/CIRCRESAHA.111.300483 (2013).
8 Rai, N., Shihan, M., Seeger, W., Schermuly, R. T. & Novoyatleva, T. Genetic Delivery and Gene Therapy in Pulmonary Hypertension. Int J Mol Sci 22, doi:10.3390/ijms22031179 (2021).
9 Carman, B. L., Predescu, D. N., Machado, R. & Predescu, S. A. Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension. Am J Pathol 189, 1133-1144, doi:10.1016/j.ajpath.2019.02.005 (2019).
10 Hoeper, M. M. et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127, 1128-1138, doi:10.1161/CIRCULATIONAHA.112.000765 (2013).
11 Aiello, V. D. et al. Morphology of the internal elastic lamina in arteries from pulmonary hypertensive patients: a confocal laser microscopy study. Mod Pathol 16, 411-416, doi:10.1097/01.MP.0000067685.57858.D7 (2003).
12 Gairhe, S., Bauer, N. N., Gebb, S. A. & McMurtry, I. F. Myoendothelial gap junctional signaling induces differentiation of pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 301, L527-535, doi:10.1152/ajplung.00091.2011 (2011).
13 Truong, U. et al. Wall shear stress measured by phase contrast cardiovascular magnetic resonance in children and adolescents with pulmonary arterial hypertension. J Cardiovasc Magn Reson 15, 81, doi:10.1186/1532-429X-15-81 (2013).
14 Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668, doi:10.1126/science.1188302 (2010).
15 Draijer, R., Atsma, D. E., van der Laarse, A. & van Hinsbergh, V. W. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 76, 199-208, doi:10.1161/01.res.76.2.199 (1995).
16 Bogatcheva, N. V., Garcia, J. G. & Verin, A. D. Molecular mechanisms of thrombin-induced endothelial cell permeability. Biochemistry (Mosc) 67, 75-84, doi:10.1023/a:1013904231324 (2002).
17 Sakolish, C. M., Esch, M. B., Hickman, J. J., Shuler, M. L. & Mahler, G. J. Modeling Barrier Tissues In Vitro: Methods, Achievements, and Challenges. EBioMedicine 5, 30-39, doi:10.1016/j.ebiom.2016.02.023 (2016).
18 Burton, V. J. et al. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 117, 333-341, doi:10.1182/blood-2010-05-285973 (2011).
19 Abdul-Salam, V. B. et al. Chloride intracellular channel protein 4 in pulmonary endothelial angiogenesis. Vasc Pharmacol 56, 361-361, doi:10.1016/j.vph.2011.08.152 (2012).
20 Sindi, H. A. et al. Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nat Commun 11, 1185, doi:10.1038/s41467-020-14966-x (2020).
21 Smits, J. et al. Blood Outgrowth and Proliferation of Endothelial Colony Forming Cells are Related to Markers of Disease Severity in Patients with Pulmonary Arterial Hypertension. Int J Mol Sci 19, doi:10.3390/ijms19123763 (2018).
22 Gorr, M. W., Sriram, K., Muthusamy, A. & Insel, P. A. Transcriptomic analysis of pulmonary artery smooth muscle cells identifies new potential therapeutic targets for idiopathic pulmonary arterial hypertension. Br J Pharmacol 177, 3505-3518, doi:10.1111/bph.15074 (2020).
23 Rhodes, C. J. et al. RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 192, 356-366, doi:10.1164/rccm.201408-1528OC (2015).
24 Reyes-Palomares, A. et al. Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension. Nat Commun 11, 1673, doi:10.1038/s41467-020-15463-x (2020).
25 Gorr, M. W., Sriram, K., Chinn, A. M., Muthusamy, A. & Insel, P. A. Transcriptomic profiles reveal differences between the right and left ventricle in normoxia and hypoxia. Physiol Rep 8, e14344, doi:10.14814/phy2.14344 (2020).
26 Shi, Z. D. & Tarbell, J. M. Fluid flow mechanotransduction in vascular smooth muscle cells and fibroblasts. Ann Biomed Eng 39, 1608-1619, doi:10.1007/s10439-011-0309-2 (2011).
27 van Engeland, N. C. A. et al. A biomimetic microfluidic model to study signalling between endothelial and vascular smooth muscle cells under hemodynamic conditions. Lab Chip 18, 1607-1620, doi:10.1039/c8lc00286j (2018).
28 Xiao, Y. et al. Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. Aging Dis 11, 1623-1639, doi:10.14336/AD.2020.0111 (2020).
29 Lebrin, F., Deckers, M., Bertolino, P. & Ten Dijke, P. TGF-beta receptor function in the endothelium. Cardiovasc Res 65, 599-608, doi:10.1016/j.cardiores.2004.10.036 (2005).
30 Morty, R. E. et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 27, 1072-1078, doi:10.1161/ATVBAHA.107.141200 (2007).
31 Maloney, J. P. et al. Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 302, L541-554, doi:10.1152/ajplung.00282.2011 (2012).
32 Lowery, J. W. et al. ID family protein expression and regulation in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 299, R1463-1477, doi:10.1152/ajpregu.00866.2009 (2010).
33 Zhang, Y. et al. E3 Ubiquitin ligase NEDD4 familyregulatory network in cardiovascular disease. Int J Biol Sci 16, 2727-2740, doi:10.7150/ijbs.48437 (2020).
34 Hiepen, C. et al. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFbeta responses and altered cell mechanics. PLoS Biol 17, e3000557, doi:10.1371/journal.pbio.3000557 (2019).
35 Zweier, J. L. & Talukder, M. A. Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: a new approach to improve vascular dysfunction? Circulation 123, 1156-1158, doi:10.1161/CIRCULATIONAHA.110.017038 (2011).
36 Leiper, J. et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13, 198-203, doi:10.1038/nm1543 (2007).
37 Rhodes, C. J. et al. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med 7, 227-238, doi:10.1016/S2213-2600(18)30409-0 (2019).
38 Gross, C. M. et al. Sox18 preserves the pulmonary endothelial barrier under conditions of increased shear stress. J Cell Physiol 229, 1802-1816, doi:10.1002/jcp.24633 (2014).
39 Eichstaedt, C. A. et al. First identification of Kruppel-like factor 2 mutation in heritable pulmonary arterial hypertension. Clin Sci (Lond) 131, 689-698, doi:10.1042/CS20160930 (2017).
40 Eyries, M. et al. Familial pulmonary arterial hypertension by KDR heterozygous loss of function. Eur Respir J 55, doi:10.1183/13993003.02165-2019 (2020).
41 Jasmin, J. F. et al. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res 63, 747-755, doi:10.1016/j.cardiores.2004.05.018 (2004).
42 Yeo, Y. et al. FGF12 (Fibroblast Growth Factor 12) Inhibits Vascular Smooth Muscle Cell Remodeling in Pulmonary Arterial Hypertension. Hypertension 76, 1778-1786, doi:10.1161/HYPERTENSIONAHA.120.15068 (2020).
43 Wojciak-Stothard, B. et al. Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res 110, 1423-1434, doi:10.1161/CIRCRESAHA.112.264473 (2012).
44 Sevilla-Perez, J. et al. Shroom expression is attenuated in pulmonary arterial hypertension. Eur Respir J 32, 871-880, doi:10.1183/09031936.00045507 (2008).
45 Ma, L. et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 369, 351-361, doi:10.1056/NEJMoa1211097 (2013).
46 Cunningham, K. P. et al. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension. J Physiol 597, 1087-1101, doi:10.1113/JP277275 (2019).
47 Zhao, L. et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455-467, doi:10.1161/CIRCULATIONAHA.112.103176 (2012).
48 Van der Feen, D. E. et al. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 200, 910-920, doi:10.1164/rccm.201812-2275OC (2019).
49 Backs, J., Song, K., Bezprozvannaya, S., Chang, S. & Olson, E. N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 116, 1853-1864, doi:10.1172/JCI27438 (2006).
50 Bull, T. M. et al. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 170, 911-919, doi:10.1164/rccm.200312-1686OC (2004).
51 Kuebler, W. M., Bonnet, S. & Tabuchi, A. Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series). Pulm Circ 8, 2045893218757596, doi:10.1177/2045893218757596 (2018).
52 Karnik, S. K. et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 130, 411-423, doi:10.1242/dev.00223 (2003).
53 Imanaka-Yoshida, K., Yoshida, T. & Miyagawa-Tomita, S. Tenascin-C in development and disease of blood vessels. Anat Rec (Hoboken) 297, 1747-1757, doi:10.1002/ar.22985 (2014).
54 Mathew, R. Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity. Am J Physiol Heart Circ Physiol 306, H15-25, doi:10.1152/ajpheart.00266.2013 (2014).
55 Andersen, C. U., Hilberg, O., Mellemkjaer, S., Nielsen-Kudsk, J. E. & Simonsen, U. Apelin and pulmonary hypertension. Pulm Circ 1, 334-346, doi:10.4103/2045-8932.87299 (2011).
56 Hendrickson, R. J. et al. Sustained pulsatile flow regulates endothelial nitric oxide synthase and cyclooxygenase expression in co-cultured vascular endothelial and smooth muscle cells. J Mol Cell Cardiol 31, 619-629, doi:10.1006/jmcc.1998.0898 (1999).
57 Zhang, S. et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 285, L740-754, doi:10.1152/ajplung.00284.2002 (2003).
58 Talati, M. & Hemnes, A. Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy. Pulm Circ 5, 269-278, doi:10.1086/681227 (2015).
59 Klomp, J. et al. Comprehensive transcriptomic profiling reveals SOX7 as an early regulator of angiogenesis in hypoxic human endothelial cells. J Biol Chem 295, 4796-4808, doi:10.1074/jbc.RA119.011822 (2020).
60 Di, R., Yang, Z., Xu, P. & Xu, Y. Silencing PDK1 limits hypoxia-induced pulmonary arterial hypertension in mice via the Akt/p70S6K signaling pathway. Exp Ther Med 18, 699-704, doi:10.3892/etm.2019.7627 (2019).
61 Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3, 187-197, doi:10.1016/j.cmet.2006.01.012 (2006).
62 Oishi, Y. & Manabe, I. Kruppel-Like Factors in Metabolic Homeostasis and Cardiometabolic Disease. Front Cardiovasc Med 5, 69, doi:10.3389/fcvm.2018.00069 (2018).
63 Leiherer, A., Geiger, K., Muendlein, A. & Drexel, H. Hypoxia induces a HIF-1alpha dependent signaling cascade to make a complex metabolic switch in SGBS-adipocytes. Mol Cell Endocrinol 383, 21-31, doi:10.1016/j.mce.2013.11.009 (2014).
64 Kawamura, Y., Tanaka, Y., Kawamori, R. & Maeda, S. Overexpression of Kruppel-like factor 7 regulates adipocytokine gene expressions in human adipocytes and inhibits glucose-induced insulin secretion in pancreatic beta-cell line. Mol Endocrinol 20, 844-856, doi:10.1210/me.2005-0138 (2006).
65 Grzegorzewska, A. P. et al. Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep 7, 41605, doi:10.1038/srep41605 (2017).
66 Jover, E. et al. Inhibition of enzymes involved in collagen cross-linking reduces vascular smooth muscle cell calcification. Faseb J 32, 4459-4469, doi:10.1096/fj.201700653R (2018).
67 Sibinga, N. E. et al. Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury. Circ Res 80, 532-541, doi:10.1161/01.res.80.4.532 (1997).
68 Xu, W. et al. Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension. Sci Rep 9, 18623, doi:10.1038/s41598-019-55053-6 (2019).
69 Corada, M. et al. Sox17 is indispensable for acquisition and maintenance of arterial identity. Nat Commun 4, 2609, doi:10.1038/ncomms3609 (2013).
70 Duong, H. T. et al. Pulmonary artery endothelium resident endothelial colony-forming cells in pulmonary arterial hypertension. Pulm Circ 1, 475-486, doi:10.4103/2045-8932.93547 (2011).
71 Al-Hilal, T. A. et al. Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application. Lab Chip 20, 3334-3345, doi:10.1039/d0lc00605j (2020).
72 Toepke, M. W. & Beebe, D. J. PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip 6, 1484-1486, doi:10.1039/b612140c (2006).
73 Allwardt, V. et al. Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption. Bioengineering (Basel) 7, doi:10.3390/bioengineering7030112 (2020).
74 Wojciak-Stothard, B. et al. Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. Circulation 129, 1770-1780, doi:10.1161/CIRCULATIONAHA.113.006797 (2014).
75 Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14, 417-419, doi:10.1038/nmeth.4197 (2017).
76 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140, doi:10.1093/bioinformatics/btp616 (2010).
77 Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47, doi:10.1093/nar/gkv007 (2015).
78 Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc 14, 482-517, doi:10.1038/s41596-018-0103-9 (2019).
79 Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1, 417-425, doi:10.1016/j.cels.2015.12.004 (2015).
80 Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27-30, doi:10.1093/nar/28.1.27 (2000).
81 Fabregat, A. et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics 18, 142, doi:10.1186/s12859-017-1559-2 (2017).
82 Maoz, B. M. et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nat Biotechnol 36, 865-+, doi:10.1038/nbt.4226 (2018).
83 Wojciak-Stothard, B. et al. Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation 129, 1770-1780, doi:10.1161/Circulationaha.113.006797 (2014).
84 Aman, J. et al. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 126, 2728-2738, doi:10.1161/CIRCULATIONAHA.112.134304 (2012).